Also known as SB-275833, {(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl} 2-({(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl}sulfanyl)acetate
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. It is marketed as an ointment under the brand names Altabax and Altargo.
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464381219 | IUPAC_name = (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propano-3aH-cyclopenta[8]annulen-8-yl{[(1R,3s,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfanyl}acetate | image = Retapamulin.svg | image_class = skin-invert-image | image2 = Retapamulin 3D sticks.png | image_class2 = bg-transparent
| tradename = Altabax, Altargo | Drugs.com = | MedlinePlus = a607049 | licence_EU = yes | licence_US = Retapamulin | pregnancy_AU = | pregnancy_US = B | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = POM | legal_US = Rx-only | legal_status = | routes_of_administration = Topical (ointment)
via Wikidata sitelinks · CC0
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).